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The tyrosine nitration of proteins has been observed in diverse
inflammatory conditions and has been linked to the presence of
reactive nitrogen species. From many in vitro experiments, it is
apparent that tyrosine nitration may alter the function of proteins.
A limited number of experiments under in vivo conditions also
demonstrate that protein nitration is associated with altered
cellular processes. To understand the association of protein nitra-
tion with the pathogenic mechanism of the disease, it is essential
to identify specific protein targets of nitration with in vivo or intact
tissue models. Using anti-nitrotyrosine antibodies, we demon-
strated the accumulation of nitrotyrosine in a 52-kDa protein in rat
kidney after lipopolysaccharide treatment. The 52-kDa protein was
purified and identified with partial sequence as succinyl-CoA:3-
oxoacid CoA-transferase (SCOT; EC 2.8.3.5). Western blot analysis
revealed that the nitration of this mitochondrial enzyme increased
in the kidneys and hearts of lipopolysaccharide-treated rats,
whereas its catalytic activity decreased. These data suggest that
tyrosine nitration may be a mechanism for the inhibition of SCOT
activity in inflammatory conditions. SCOT is a key enzyme for
ketone body utilization. Thus, tyrosine nitration of the enzyme
with sepsis or inflammation may explain the altered metabolism of
ketone bodies present in these disorders.
protein nitration u lipopolysaccharide u nitric oxide
Infection and inflammation have been associated with anincreased generation of reactive oxygen and nitrogen oxide
species. These intermediates react with proteins, lipids, and
DNA and may serve several physiological and pathophysiolog-
ical functions (1). One product of the reaction of these reactive
species with proteins is 3-nitrotyrosine (2). Initially, it was
believed that 3-nitrotyrosine was formed almost exclusively by
the reaction of tyrosine with peroxynitrite, a potent oxidant
formed by the reaction of nitric oxide and superoxide anion (3).
Recently, it has become recognized that other reactions, for
example those involving hypochlorous acid and peroxidase
enzymes, also may give a rise to nitration reactions (4). The
mechanism(s) by which tyrosine is nitrated in vivo remains an
area of active investigation and controversy (4–9).
Apart from the mechanism of tyrosine nitration, its biological
significance is also a subject of great interest. The formation of
3-nitrotyrosine has been identified in many diverse pathological
conditions such as atherosclerosis, pulmonary and heart disease,
chronic rejection of transplanted organs, viral infections, and
neurological disorders (for review, see ref. 10). However, many
specific proteins, which undergo nitration in human disease as
well as in animal and cellular models of disease, remain to be
identified. In vitro studies using peroxynitrite and other nitrating
agents have shown that the activity of many mammalian proteins
is altered by nitration of tyrosine residue(s) (for review, see ref.
10). In addition to alterations in the structure and function of
proteins, nitration of tyrosine residues may prevent tyrosine
phosphorylation (11, 12). Despite the information generated
from such in vitro experiments, the exact physiological relevance
and functional consequences of this posttranslational protein
modification remain obscure. Overall, many studies view ty-
rosine nitration as an incidental process with perhaps no phys-
iologic consequence. However, a list of nitrotyrosine-containing
proteins identified from in vivo studies is too limited (13–19) to
draw any clear conclusion. With in vivo studies, it has been
suggested that protein nitration may inhibit, activate, or have no
effect on the protein’s function.
Inflammation can cause a derangement of host metabolism
and may lead to organ dysfunction or failure. Many of the
systemic changes observed during inflammation can be dupli-
cated by in vivo treatment of animals with lipopolysaccharide
(LPS, endotoxin) from the Gram-negative bacteria outer mem-
brane (20). In an attempt to understand whether inflammation
caused tyrosine nitration of specific proteins and altered their
activity, tissues from LPS-treated rats were screened for ty-
rosine-nitrated proteins by using Western immunoblots of tissue
extracts with an anti-nitrotyrosine antibody. We observed sev-
eral nitrated proteins in our screening. One of the nitrated
proteins in kidney extracts was purified, partially sequenced, and
identified as succinyl-CoA:3-oxoacid CoA-transferase (SCOT;
EC 2.8.3.5). We demonstrate here that LPS administration
enhanced SCOT nitration and decreased its catalytic activity in
rat kidney and heart. These data may explain the altered ketone
body metabolism during sepsis or inflammation.
Materials and Methods
Materials. LPS (from Escherichia coli, serotype 0111:B4), tetra-
nitromethane, soybean trypsin inhibitor, aprotinin, leupeptin,
pepstatin A, antipain, phenylmethylsulfonyl f luoride, N-tosyl-L-
phenylalanine chloromethyl ketone, Na-p-tosyl-L-lysine chlo-
romethyl ketone, 2-thiobarbituric acid, polyoxyethylene ester
W-1, malonaldehyde bis(dimethyl acetal), succinyl-CoA, and
acetoacetate (lithium salt) were purchased from Sigma. Ceramic
hydroxyapatite and Affi-Gel Blue agarose were obtained from
Bio-Rad. Sephacryl S-200 high resolution was from Amersham
Pharmacia. Mouse monoclonal anti-nitrotyrosine antibody was
purchased from Upstate Biotechnology (Lake Placid, NY).
Tissue Samples. Male Wistar rats (median body weight, 250 g)
were from Harlan Breeders (Indianapolis). Animals were main-
tained on standard rat chow and tap water ad libitum. LPS was
dissolved in sterile saline and injected i.p. at a dose of 20 mgykg
body weight. Control rats received the corresponding volume of
saline. Rats were killed at 6, 9, 16, or 24 h after LPS injection.
The tissues were rapidly excised, immediately frozen in liquid
nitrogen, and stored at 280°C until further processing.
To prepare tissue extracts, the thawed tissues were homoge-
nized in 50 mM sodium phosphate buffer (pH 7.2)y0.15 M NaCl
containing protease inhibitors (10 mg/ml soybean trypsin inhib-
itory64 mM benzamidiney0.005 unit/ml aprotininy22 mM leu-
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peptiny15 mM pepstatin Ay8 mM antipainy200 mM phenyl-
methylsulfonyl f luoridey500 mM N-tosyl-L-phenylalanine
chloromethyl ketoney500 mM Na-p-tosyl-L-lysine chloromethyl
ketone). Homogenates were centrifuged for 10 min at 1,500 3 g,
and the supernatant fractions were centrifuged again for 60 min
at 100,000 3 g. The supernatant fractions from the high-speed
centrifugation were considered to contain the total soluble
protein of the tissue (i.e., cytoplasm and mitochondrial matrix).
Total protein concentrations were determined by using Bio-Rad
protein assay with BSA as the standard. The high-speed super-
natant fractions were used for all of the following experiments.
Western Blot Analysis. After separation by reducing SDSyPAGE
in 10% gel, proteins were electrophoretically transferred to
poly(vinylidene dif luoride) (PVDF) membranes (Bio-Rad),
which were blocked with 5% nonfat milk in 20 mM TriszHCl, pH
7.2y0.3 M NaCly0.1% Tween 20 (TBSyT). Membranes were
incubated with monoclonal anti-nitrotyrosine antibodies
(1:2,000 dilution, Upstate Biotechnology). After washing with
TBSyT, immunoreactive proteins were detected by using horse-
radish peroxidase-conjugated secondary antibodies and en-
hanced chemiluminescence. Control experiments for nitroty-
rosine immunoreactivity were performed by preincubating (30
min at room temperature) the anti-nitrotyrosine antibodies with
4 mM free 3-nitrotyrosine or with 4 mM free L-tyrosine before
incubation with PVDF membranes.
Rabbit polyclonal anti-SCOT antibody was generated against
KGPKFEKRIERL peptide (BioSource International, Cama-
rillo, CA) and used for Western blot analysis to normalize the
amount of SCOT in samples assayed. Preliminary Western
immunoblot experiments for SCOT also were performed with a
polyclonal antibody kindly provided by T. Fukao and N. Kondo
(Gifu University, Gifu, Japan).
Purification and Identification of the Nitrated 52-kDa Protein. The
high-speed supernatant fraction (1.3 ml containing 18 mg of
protein) from the kidneys of rat after 6 h of LPS treatment was
loaded on a Sephacryl S-200 HR column (1 3 100 cm) equili-
brated with 10 mM sodium phosphate buffer (pH 7.2) containing
0.3 M NaCl and chromatographed in the same buffer at a flow
rate of 10 mlyh. Collected fractions were analyzed with Western
blotting by using monoclonal anti-nitrotyrosine antibodies from
Upstate Biotechnology. Fractions that contained the 52-kDa
nitrated protein were pooled and loaded onto a hydroxyapatite
column (1 3 2 cm) equilibrated with 10 mM sodium phosphate
buffer (pH 7.2). Bound proteins were eluted with a step gradient
of increasing sodium phosphate concentration (50, 100, 150, and
200 mM) at a flow rate of 6 mlyh. The pool containing the
52-kDa nitrated protein was diluted with 2 vol of ice-cold
deionized water and loaded onto an Affi-Gel Blue agarose
column (1 3 1 cm) equilibrated with 50 mM sodium phosphate
buffer (pH 7.2). After washing with 200 mM sodium phosphate
buffer (pH 7.2), the bound proteins were eluted with a 1% SDS
solution.
The SDS-eluted sample was resolved by SDSyPAGE, trans-
ferred to PVDF membrane, and briefly stained with Coomassie
blue R-250. The 52-kDa nitrated band was excised and sent to
the Protein Chemistry Core Laboratory at Baylor College of
Medicine (Houston) for microsequencing analysis.
Catalytic Activity of SCOT. SCOT activity was measured by using
the assay procedure described by Williamson et al. (21). Briefly,
the incubation mixture contained 50 mM TriszHCl, pH 8.5y0.2
mM succinyl-CoAy0.1–10 mM acetoacetatey10 mM MgCl2y4
mM iodoacetamide, and high-speed supernatant fractions (300
mg of total proteinyml). SCOT catalytic activity was measured
spectrophotometrically by following the formation of aceto-
acetyl-CoA (the forward direction) at 313 nm. SCOT catalytic
activity was normalized to the total protein in high-speed
supernatants, as Western blot analysis of these supernatants with
anti-SCOT antibodies revealed similar amounts of SCOT
present.
Fig. 1. Western immunoblots using anti-nitrotyrosine antibodies. Lane 1, 50 ng of nitrated BSA. BSA was nitrated with 20-fold molar excess of tetranitrometh-
ane, dialyzed, and used as a positive control. Lane 2, 20 mg of a high-speed supernatant fraction from the kidneys of an LPS-treated rat (6 h after injection). After
separation by reducing SDSyPAGE on 10% gel, proteins were transferred to PVDF membranes. Nitrated proteins were detected with Upstate Biotechnology
monoclonal anti-nitrotyrosine antibodies (A). Control experiments for nitrotyrosine immunoreactivity were performed in the absence of primary antibody (B)
or by preincubating (30 min at room temperature) the anti-nitrotyrosine antibody with 4 mM free 3-nitrotyrosine (C) or with 4 mM free L-tyrosine (D) before
incubation with PVDF membranes.
Fig. 2. Purified 52-kDa nitrated protein from rat kidney 6 h after LPS
injection. Lane 1, molecular mass standards; lane 2, 3 mg of 52-kDa protein
after Affi-Gel Blue agarose column. The molecular masses (kDa) of protein
standards are indicated on the left. Coomassie-stained SDS-polyacrylamide
gel (A) and Western immunoblots with Upstate Biotechnology monoclonal
anti-nitrotyrosine antibody (B) or with polyclonal anti-SCOT antibody (C) are
shown.
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Determination of Thiobarbituric Acid-Reactive Substances (TBARS) in
Mitochondria. Mitochondria from kidney, heart, and brain were
isolated by using differential centrifugation. Tissues from control
rats and rats 6 h after LPS injection were minced with scissors
and homogenized in a glass homogenizer with a motor-driven
Teflon pestle in 10 mM phosphate buffer, pH 7.2y0.5 mM
EDTAy0.25 M sucrose. After centrifugation at 750 3 g for 10
min, the supernatant fractions were centrifuged at 10,000 3 g for
20 min. Pellets were washed twice with 10 mM phosphate buffer,
pH 7.2y0.5 mM EDTAy0.25 M sucrose. After the final wash,
mitochondria were resuspended in 20 mM phosphate buffer (pH
7.2), and aliquots were quick-frozen in liquid nitrogen.
To measure TBARS, mitochondria were disrupted by four
freeze-thawing cycles. Three hundred microliters of mitochon-
drial suspension (4 mg of total proteinyml) was mixed with 100
ml of a 10% solution of polyoxyethylene ester W-1 (nonionic
detergent), 100 ml of 75% trichloroacetic acid, and 500 ml of an
aqueous solution containing 0.6% 2-thiobarbituric acid. The
reaction mixture was heated in boiling water for 30 min and
centrifuged, and the absorbance was measured at 532 nm against
a reaction mixture blank. The amounts of TBARS were calcu-
lated by using malonaldehyde bis(dimethyl acetal) as a standard.
Statistical Analysis. Results of SCOT enzymatic activity are shown
as the mean 6 SEM. The results obtained from kidneys of
LPS-treated rats were analyzed by ANOVA followed by Bon-
ferroni’s modified t test, whereas the other results were analyzed
by unpaired t test.
Results
The 52-kDa Tyrosine Nitrated Protein in Rat Kidneys. Western blot
analysis of tissue extracts from kidneys of control and LPS-
treated rats revealed several tyrosine-nitrated proteins. Here, we
report a protein with an apparent molecular mass of 52 kDa (Fig.
1). Tyrosine-nitrated BSA (Fig. 1, lane 1) and the high-speed
supernatant fraction from rat kidney after 6 h of LPS treatment
(Fig. 1, lane 2) were resolved on a 10% gel by reducing
SDSyPAGE, transferred to a PVDF membrane, and cut into
strips. Strips were separately examined with a monoclonal
antibody against nitrotyrosine (Fig. 1 A), without primary anti-
body (Fig. 1B), and with a monoclonal antibody against nitro-
tyrosine that was preincubated with 4 mM free nitrotyrosine
(Fig. 1C) or with 4 mM free L-tyrosine (Fig. 1D). Therefore, Fig.
1 represents a combination of negative and positive controls for
this protein, which indicates the specificity of nitrotyrosine
immunodetection.
To purify this 52-kDa protein, we used a combination of
different protein separation methods and analyzed each separate
fraction by Western blot using an anti-nitrotyrosine antibody.
The procedure of purification is described in Materials and
Methods in detail. Fig. 2A shows that gel filtration on the
Sephacryl S-200 and chromatographies on hydroxyapatite and
Affi-Gel Blue agarose result in substantial purification of the
tyrosine-nitrated (Fig. 2B) 52-kDa protein. N-terminal sequenc-
ing of this protein revealed the Thr-Lys-Phe-Tyr-Thr-Asp-Pro-
Val-Glu-Ala-Val sequence, which corresponds to the first 11
residues of the mature SCOT. A rabbit polyclonal anti-SCOT
antibody was generated against a peptide fragment of SCOT (see
Materials and Methods) and used for Western analysis to confirm
that the 52-kDa nitrated protein was indeed SCOT (Fig. 2C).
SCOT Sequence Analysis. SCOT is a mitochondrial matrix ho-
modimer. The rat SCOT sequence is not available. The human
(22) and pig (23) amino acid sequences possess more than 90%
identity and contain 520 residues each. This includes the mito-
chondrial leader peptide (1–39 aa residues), which is absent in
the mature enzyme (40–520 aa residues). The mature human and
pig sequences contain 11 and 12 tyrosine residues, respectively.
The PREDACC program (http:yycondor.urbb.jussieu.fry) was
used to predict the solvent accessibility of the amino acids of the
human and pig enzymes. Two invariant tyrosines (Tyr-126 and
Tyr-174) were predicted to be ‘‘external’’ with probability 73%
and 74%, respectively. Although the site of nitration has not
been identified, these two residues likely represent the best
candidates for nitration because the major factor that determines
the selectivity of protein tyrosine nitration is the solvent acces-
sibility of tyrosine residues (24).
SCOT Nitration in Rat Tissues. Heart and kidney are the tissues that
contain the most SCOT activity in rat (21). At least 10-fold lower
SCOT activities were detected in rat brain and skeletal muscle,
followed by trace activities in lung and spleen. No SCOT activity has
been detected in liver (21). Western immunoblot and Northern blot
studies on SCOT distribution in human tissues revealed a high level
of SCOT expression in heart and kidney, a reduced expression in
brain and skeletal muscle, and a low level of SCOT expression in
lung. No SCOT was identified in liver (25).
Fig. 3B shows the immunodetection of SCOT in high-speed
supernatant fractions from various rat tissues 6 h after LPS
injection. Our data are consistent with those previously pub-
lished (21, 25) and show a high level of SCOT in heart and
kidney, less amounts of SCOT in brain and skeletal muscle, trace
Fig. 3. Western immunoblots of various rat tissue extracts 6 h after LPS
injection. Twenty micrograms of high-speed supernatant fractions was loaded
per lane. Proteins transferred to the PVDF membrane were analyzed with
Upstate Biotechnology monoclonal anti-nitrotyrosine antibody (A) or with
polyclonal anti-SCOT antibody (B). Lanes 1–7 correspond to heart, kidney,
brain, skeletal muscle, liver, lung, and spleen, respectively.
Fig. 4. LPS treatment enhanced SCOT nitration in rat kidney. Forty micrograms of the high-speed supernatant fractions was loaded per lane. Proteins
transferred to the PVDF membrane were analyzed with Upstate Biotechnology monoclonal anti-nitrotyrosine antibody (A) or polyclonal anti-SCOT antibody (B).
Lanes 1–5 correspond to 0, 6, 9, 16, and 24 h after LPS injection, respectively.
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amounts in lung and spleen, and no SCOT in liver. Fig. 3A shows
the immunodetection of nitrotyrosine in the same samples.
There is no detectable amount of nitrated SCOT in brain,
skeletal muscle, liver, lung, or spleen. There is some nitrated
SCOT in heart, and the strongest detection of nitrated SCOT was
in kidney. Thus, tyrosine nitration of SCOT after LPS treatment
occurs in a tissue-specific manner. Furthermore, the amounts of
SCOT in heart and kidney do not differ substantially with respect
to total protein, whereas tyrosine nitration was more favorable
in kidney versus heart.
SCOT Catalytic Activity. The presence of nitrated SCOT in untreated
rat kidneys was observed (Fig. 4A). However, LPS treatment
resulted in an increase of SCOT nitration (Fig. 4A). Fig. 4B shows
that the abundance of SCOT protein was equal in all lanes. The
catalytic activity of SCOT is shown in Table 1. The asterisk indicates
statistically significant data. After 6 h of LPS treatment, a statisti-
cally significant decrease in SCOT activity was observed in kidney
(Table 1), which was accompanied by an increase in SCOT nitration
(Fig. 4A). Whereas SCOT also had increased nitration at 9, 16, and
24 h after LPS (Fig. 4A), the enzyme activity was not significantly
decreased as it was at 6 h after LPS (Table 1). A statistically
significant decrease in SCOT activity also was found in heart after
LPS treatment (Table 1). Similar to kidney, this change also was
accompanied by an increase of SCOT nitration in heart upon LPS
treatment (data not shown). We did not observe SCOT nitration in
brain (Fig. 3A), and no changes in SCOT catalytic activity were
detected (Table 1).
Besides tyrosine, other amino acid residues also are susceptible
to modification in inflammatory conditions. We assume that in-
creased tyrosine nitration after LPS treatment is the primary reason
for the inactivation of SCOT. However, to be sure of this assump-
tion, the degree of SCOT nitration without alterations of other
amino acids, such as tryptophan, cysteine, and methionine will have
to be determined experimentally in future studies.
Mitochondrial Lipid Peroxidation. Generation of free radicals in
mitochondria is well documented (26, 27). Superoxide and nitric
oxide radicals react to produce peroxynitrite, which may cause
protein tyrosine nitration. Peroxynitrite is a strong oxidant that
also can induce membrane lipid peroxidation (28). As a measure
of lipid peroxidation, the thiobarbituric acid test was used. This
test estimates the amount of malondialdehyde precursors, in-
cluding hydroperoxides and endoperoxides. Fig. 5 shows the
formation of TBARS in kidney, heart, and brain mitochondria
from control and 6-h LPS-treated rats. LPS treatment induced
increases in mitochondrial lipid peroxidation in kidney and
heart. No significant increase was observed in brain. The results
presented in Fig. 5 are consistent with the notion that mitochon-
dria from LPS-treated animals were exposed to an increased
level of oxidative stress.
Discussion
Protein tyrosine nitration in the kidney has been detected in a
number of pathological conditions, such as human renal allograft
Fig. 5. Levels of lipid peroxidation in kidney, heart, and
brain. TBARS were quantified in mitochondria from con-
trol rats and from rats 6 h after LPS injection and were
expressed as pmol of TBARS formed per mg of total
protein. Values are the mean 6 SEM (n 5 3 rats in each
group); *, P , 0.05 compared with the corresponding
control value.
Table 1. LPS treatment decreases SCOT catalytic activity
Rat tissue
Time after LPS
injection, h
SCOT catalytic activity,
nmol per min per mg
Kidney 0 79.8 6 2.4 (4)
6 63.5 6 4.8* (4)
9 65.0 6 5.6 (4)
16 76.0 6 5.4 (5)
24 76.7 6 0.8 (3)
Heart 0 105.3 6 6.8 (3)
6 84.7 6 5.3* (3)
Brain 0 22.4 6 0.3 (3)
6 25.6 6 1.2 (3)
The forward direction of the SCOT catalytic reaction was measured. Cata-
lytic activity was expressed as nmol of acetoacetyl-CoA formed per min per mg
of total protein. Data represent mean 6 SEM. Number of animals used is
shown in parentheses. *, P , 0.05.
Marcondes et al. PNAS u June 19, 2001 u vol. 98 u no. 13 u 7149
BI
O
CH
EM
IS
TR
Y
rejection (13), experimental glomerulonephritis (29), diabetic
nephropathy (30), LPS-induced kidney injury (31), transgenic
sickle cell mice (32), IL-1b-treated mesangial cells (33), and the
Goldblatt animal model for hypertension (34). However, Mn
superoxide dismutase (13) and prostacyclin synthase (33) are the
only previously reported proteins that are modified by nitration
in kidney. In the present study, we report an additional tyrosine-
nitrated protein in rat kidney, SCOT.
SCOT is localized exclusively in the mitochondrial matrix. Our
findings suggest that there is an association between LPS admin-
istration, mitochondrial lipid peroxidation, SCOT nitration, and
SCOT inactivation. It is important to recognize that both processes,
lipid peroxidation and protein tyrosine nitration, could be a result
of peroxynitrite formation. However, it should be noted that
mitochondrial lipid peroxidation is not a specific indicator of
mitochondrial peroxynitrite formation. Agents other than per-
oxynitrite can cause lipid peroxidation. Furthermore, although our
data demonstrate that SCOT nitration is accompanied by SCOT
inactivation, they do not necessarily establish that tyrosine nitration
is the only factor responsible for the decrease in SCOT catalytic
activity. Other amino acid residues in SCOT also could be modified
with the conditions favorable for tyrosine nitration. Furthermore,
at 9, 16, and 24 h after LPS administration, SCOT contained
nitrotyrosine (Fig. 4A), whereas the enzyme activity was not
significantly altered from control value (Table 1).
SCOT catalyzes the formation of acetoacetyl CoA from
acetoacetate. This is the rate-determining step in ketolysis, which
is the process of ketone body conversion into energy in the
extrahepatic organs, such as heart, kidney, brain, and skeletal
muscle (35). The term ketone bodies refers to three molecules.
The two major ketone bodies are acetoacetate and 3-b-
hydroxybutyrate, and acetone is the third one and is least
abundant. The ketone body 3-b-hydroxybutyrate is formed by
the reduction of acetoacetate. These two ketone bodies serve as
an alternative source of energy during periods of glucose defi-
ciency, such as starvation or prolonged exercise. Ketone body
metabolism includes both ketogenesis and ketolysis (Fig. 6).
Ketogenesis is the process by which free fatty acids are trans-
formed into acetoacetate and 3-b-hydroxybutyrate in liver (35).
The putative mechanism of organ dysfunction during inflam-
mation is a disruption of cellular energetics. It is well known that
the rate of hepatic ketogenesis is diminished (Fig. 6) during an
inflammatory state despite the availability of excess free fatty
acids supplied to the liver (36, 37). The antiketogenic effect of
inflammation results in a decrease in the plasma levels of ketone
bodies. The decrease in the availability of circulating ketone
bodies increases the dependence on other sources of energy and
may have adverse consequences while systemic metabolism is
changed by the inflammatory process.
The major observations of this study are (i) the catalytic activity
of SCOT in kidney is impaired after LPS administration and (ii) this
impairment is accompanied by SCOT tyrosine nitration. Overall,
these data suggest that in addition to the antiketogenic effect,
inflammation or endotoxin also may result in decreased efficiency
of ketone body utilization (Fig. 6) through inactivation of the key
enzyme of ketolysis, SCOT. Perhaps, in addition to other delete-
rious changes caused by inflammation or endotoxin, impaired
ketone body utilization may represent another adverse contributing
factor. Additional studies will be required to determine the specific
tyrosine residue(s) in SCOT that is nitrated and the stoichiometry
of tyrosine nitration with altered enzyme activity. As discussed
above, other modifications of SCOT cannot be excluded to explain
some of our observations.
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